VEGFA and neoplasm: In the absence of randomized trials wherein time-to-event endpoints such as time to tumor progression can be reliably compared with a control group [8,10], surrogate biomarkers are needed to help validate the mechanistic hypotheses of action, identify responsive patients and optimal biologic doses, and predict the outcomes of regimens that include anti-VEGF agents.